Teva Pharmaceutical Industries (TEVA) versus Its Peers Head to Head Review

Teva Pharmaceutical Industries (NYSE:TEVA) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Teva Pharmaceutical Industries to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk.

Institutional and Insider Ownership

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Teva Pharmaceutical Industries and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	2.94%	33.20%	6.59%
Teva Pharmaceutical Industries Competitors	-2,380.38%	-217.94%	-15.54%

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries’ competitors have a beta of -3.71, meaning that their average share price is 471% less volatile than the S&P 500.

Dividends

Teva Pharmaceutical Industries pays an annual dividend of $1.01 per share and has a dividend yield of 2.4%. Teva Pharmaceutical Industries pays out 235.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend. Teva Pharmaceutical Industries lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.

Analyst Recommendations

This is a summary of recent ratings for Teva Pharmaceutical Industries and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1	1	13	0	2.80
Teva Pharmaceutical Industries Competitors	7798	13888	25778	1037	2.41

Teva Pharmaceutical Industries presently has a consensus target price of $47.23, suggesting a potential upside of 11.08%. As a group, “Pharmaceuticals” companies have a potential upside of 25.68%. Given Teva Pharmaceutical Industries’ competitors higher possible upside, analysts clearly believe Teva Pharmaceutical Industries has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Teva Pharmaceutical Industries and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.23 billion	$1.41 billion	98.88
Teva Pharmaceutical Industries Competitors	$3.56 billion	$3.19 billion	555.10

Teva Pharmaceutical Industries has higher revenue, but lower earnings than its competitors. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Teva Pharmaceutical Industries beats its competitors on 8 of the 15 factors compared.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.